Press Release

Conference call and live webcast to be held Monday, May 18 th at 3:00pm ET Wall Street firm publishes research report refuting claims made by recent unaffiliated   third-party article; Research report also references Vascular Surgeon who categorically disputes many of the assertions that were

Recent transition to the Full Market Release has already resulted in increased revenue for the current Q2, which has already exceeded Q1 revenue, as utilization and adoption of the LIBERTY System accelerates across multiple sales territories Company experiencing increase in recurring customer

Commercial adoption of the LIBERTY System by sites that participated in the clinical trial serves as a strong validation of the value it brings to everyday practice The Company will attend the Annual Global Embolization Symposium & Technologies (GEST), a Premier Medical Conference in New York City

Commencement of activities in international markets is supported by the successful completion of the Limited Market Release, followed by the Recent Full Market Release in the U.S.  Strong physician interest at recent Society of Interventional Radiology conference and rising awareness across markets

Members of the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Represent the Largest Addressable User Market for the LIBERTY System At least Nine Medical Societies Endorse Updated Guidelines to Lower Radiation Exposure and

The presentation will be webcast live on April 15 at 10:15 a.m. ET. Continued Engagement with Healthcare Institutions Reflects Rising Momentum HINGHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular

Successful Execution of the Limited Market Release (LMR) Includes Adoption by Globally Recognized Healthcare Systems in the U.S. Market and Demonstrates Broad Market Scalability in Key Endovascular Procedures HINGHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc.

World’s first robotic Prostatic Artery Embolization (PAE) for   Benign Prostatic Hyperplasia   (BPH)   and robotic Y-90 radioembolization mapping for liver cancer are among the robotic cases performed using the LIBERTY System, demonstrating system adoption across multiple case types ATLANTA and

Being Published in the Journal of Vascular and Interventional Radiology, a Premier Peer-Reviewed Journal, Speaks to the Quality and Impact of the Study Company Remains Focused on Expanding Evidence-Based Data to Support Broader Commercial Adoption of the LIBERTY System HINGHAM, Mass., March 24,